<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTER-DEALER QUOTATION SYSTEM FILED PURSUANT TO
SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934 AND RULES 13A-17 AND 15D-17 THEREUNDER
Cytocare, Inc.
------------------------------------------------------------------------------
(Exact Name of Issuer as Specified in Charter)
100 Columbia, Suite 100, Aliso Viejo, CA 92656
------------------------------------------------------------------------------
(Address of Principal Executive Officers)
(714) 448-7700
------------------------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or
more in the number of shares outstanding:
1. Title of security _____________________________________________
2. Number of shares outstanding before the change ________________
3. Number of shares outstanding after the change _________________
4. Effective date of change ______________________________________
5. Method of change:
Specify method (such as merger, acquisition, exchange,
distribution, stock split, reverse split, acquisition of stock for
treasury, etc.)
___________________________________________________________________
Give brief description of transaction _____________________
___________________________________________________________________
II. CHANGE IN NAME OF ISSUER
1. Name prior to change Cytocare, Inc.
-----------------------------------------------
2. Name after change Medstone International, Inc.
-------------------------------------------------
3. Effective date of charter amendment changing name Sept. 21, 1995
-----------------
4. Date of shareholder approval of change, if required Sept. 21, 1995
---------------
Date September 22, 1995 David V. Radlinski, CFO and Secretary
------------------------ -------------------------------------------
(Officer's Signature and Title)
